… to the effective inhibition of tumor growth in mice … degrader for the treatment of prostate
cancer and provides insights and guidance into the design of orally active PROTAC degraders. …

… therapy for prostate cancer … degradation via Proteolysis Targeting Chimeras (PROTACs)
will be a better therapeutic strategy for targeting androgen receptor signaling in prostate cancer …

… target for the treatment of prostate cancer. We report herein the design… chimeras (PROTAC)
androgen receptor (AR) degraders, such as compound A031. It could induce the degradation …

… This article reviews PROTAC-mediated degradation of critical oncoproteins in cancer, …
BRD4 degradation in HEK293T cells and reduced the viability of prostate carcinoma 22Rv1 …

… degraders of androgen receptor (AR), as exemplified by compound 34 (ARD-69). ARD-69
induces degradation of AR protein in AR-positive prostate cancer … AR+ prostate cancer cell …

… ) degrader, a series of novel proteolysis targeting chimeras (… evaluated for their AR degradation
activity against LNCaP (AR… affinity (85%) and degradation activity against AR. Due to the …

… therapeutic target to block AR signaling in prostate cancer cells. We demonstrated that
utilizing PROTAC for induced AR protein degradation via NTD represents an efficient alternative …

… -targeting chimera degrader. ARD-… degradation in both the LNCaP and VCaP prostate
cancer cell lines, potently and effectively suppresses AR-regulated genes, and inhibits cancer cell …

… for protein degraders that target the androgen receptor, the oestrogen receptor and BTK
have shown encouraging clinical activity in patients with prostate cancer, breast cancer and …

… PROTAC drug demonstrated effective p300 degradation and cancer cell-killing capabilities
in … models, the p300 PROTAC drug showed potent p300 degradation and tumor suppression. …